Valneva SE (VALN)
Valneva SE at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Valneva SE (VALN) is a Biotechnology company based in FR with a market capitalization of $467.5M. Revenue grew 3.0% year-over-year and free cash flow was negative at -$65.6M. This page tracks VALN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
FR · 713 employees · IPO May 5, 2021
Valuation
Valuation & price
$5.68as of May 17, 2026· -53.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
4.40
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$467.5M
Market cap
3.0%
Revenue growth (YoY)
38.7%
Gross margin
-$65.6M
Free cash flow (USD)
$97.6M
Net debt
19.7%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 22, 2026Filing
Financial Results Announcement
- 6-K filingJun 25, 2026Filing
Annual General Meeting Results
- 6-K filingJun 5, 2026Filing
Annual General Meeting Documentation
- 6-K filingJun 1, 2026Filing
Investor Conferences Participation
- Annual reportMay 13, 2026Filing
Annual Report Filed
- 6-K filingMay 5, 2026Filing
Financial Results Announcement
- 6-K filingApr 30, 2026Filing
Securities Purchase Agreement
Questions
Frequently asked questions
What is Valneva SE's market cap?
Valneva SE (VALN) has a market capitalization of $467.5M.
What is VALN's P/E ratio?
A meaningful P/E ratio is not available for VALN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is VALN's price-to-book (P/B) ratio?
VALN trades at 4.40 times book value per share.
Are insiders buying VALN stock?
SEC Form 4 filings show no open-market insider buys at Valneva SE in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.